Promega Corporation

AMPK (A1/B1/G2) Kinase Enzyme System

See All Kinase Enzyme Systems
Recombinant full-length human AMPK (combination of A1/B1/G2 subunits) was expressed by baculovirus in Sf9 insect cells using a C-terminal His tag. AMP-activated protein kinase (AMPK) exhibits a key role as a master regulator of cellular energy homeostasis (1). AMPK exists as a heterotrimeric complex composed of a catalytic α subunit and regulatory β and γ subunits. Binding of AMP to the γ subunit allosterically activates the complex. AMPK is activated in response to stresses that deplete cellular ATP (low glucose, hypoxia and ischemia) (2) and via signaling pathway...

Expand to Read More »

  • Share
  • Print
  • Email
  • Prices valid for customers of Promega France only
Product Size Conc. Catalog # *List Price Order QTY Add to Cart
AMPK (A1/B1/G2) Kinase Enzyme System
Close Window

AMPK (A1/B1/G2) Kinase Enzyme System  Components

10μg
- V4012 € 364,00 Add to cart

AMPK (A1/B1/G2) Kinase Enzyme System

Close Window

AMPK (A1/B1/G2) Kinase Enzyme System

 Components

1mg
- V6274 € 5 610,00 Add to cart
ADP-Glo™ Kinase Assay + AMPK (A1/B1/G2) Kinase Enzyme System
Close Window

ADP-Glo™ Kinase Assay + AMPK (A1/B1/G2) Kinase Enzyme System  Components

  • AMPK (A1/B1/G2) Kinase Enzyme System

    V40121 x 10μg
  • ADP-Glo™ Kinase Assay

    V91011 x 1,000 assays
1 each
- V4013 € 738,00 Add to cart


You Also May Be Interested In

Storage Conditions

Upon receipt, centrifuge the kinase and dispense it into smaller quantities. Store the kinase at –70°C and the rest of the components at –20°C.

For product intended use please see Patents & Disclaimers tab.

Use Restrictions

V4012, V6274, V4013 For Research Use Only. Not for Use in Diagnostic Procedures.

Patents - Disclaimers

V4013 U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

V4013 U.S. Pat. No. 7,700,310 and other patents and patents pending.

V4013 U.S. Pat. No. 7,741,067 and other patents and patents pending.

V4013 U.S. Pat. Nos. 6,602,677, 7,241,584 and 8,030,017 and other patents and patents pending.

V4013 U.S. Pat. No. 8,183,007 and other patents pending.

V4013 Licensed from Lonza Nottingham Ltd. under U.S. Pat. Nos. 6,599,711 and 6,911,319 and other pending and issued patents.

V4013 The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.

Prefer a different language?

Your country is set to France. Your language is set to français. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.